Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors

Leukemia Research

Volumn 39, Issue 1, 2015, Pages 58-64

  Lipton, J H ^a   Bryden, P ^b   Sidhu, M K ^c   Huang, H ^d   McGarry, L J ^d   Lustgarten, S ^d   Mealing, S ^b   Woods, B ^b   Whelan, J ^b   Hawkins, N ^b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b ICON PLC   (United Kingdom)

^c ICON Health Economics   (United States)

^d ARIAD PHARMACEUTICALS INC   (United States)

Author keywords

CML; Ponatinib; Response; Second generation tyrosine kinase inhibitor; Systematic review

Indexed keywords

BAFETINIB; BOSUTINIB; DASATINIB; HOMOHARRINGTONINE; NILOTINIB; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR; PROTEIN KINASE INHIBITOR;

ADULT; ARTICLE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CYTOGENETICS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PROBABILITY; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT RESPONSE; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MORTALITY; SURVIVAL RATE;

DISEASE-FREE SURVIVAL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROTEIN KINASE INHIBITORS; SURVIVAL RATE;

EID: 84920400039     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.10.005     Document Type: Article

References (33)

1. Baccarani M., Deininger M.W., Rosti G., Hochhaus A., Soverini S., Apperley J.F., et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013, 122:872-884.
2. Hochhaus A., Baccarani M., Deininger M., Apperley J.F., Lipton J.H., Goldberg S.L., et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008, 22:1200-1206.
3. Kantarjian H., Pasquini R., Levy V., Jootar S., Holowiecki J., Hamerschlak N., et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer 2009, 115:4136-4147.
4. Kantarjian H.M., Giles F.J., Bhalla K.N., Pinilla-Ibarz J., Larson R.A., Gattermann N., et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 2011, 117:1141-1145.
5. Pfizer Bosulif Prescribing Information, Sep 2013. 2013.
6. O'Hare T., Eide C.A., Deininger M.W.N. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007, 110:2242-2249.
7. O'Hare T., Shakespeare W.C., Zhu X., Eide C.A., Rivera V.M., Wang F., et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009, 16:401-412.
8. Redaelli S., Piazza R., Rostagno R., Magistroni V., Perini P., Marega M., et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol 2009, 27:469-471.
9. Shah N.P., Cortes J.E., Kim D-W., Nicolini F.E., Talpaz M., Baccarani M., et al. Impact of baseline (BL) mutations, including low-level and compound mutations, on ponatinib response and end of treatment (EOT) mutation analysis in patients (Pts) with chronic phase chronic myeloid leukemia (CP-CML). Blood 2013, 122:652.
10. ARIAD Pharmaceuticals Inc. Press release. Cambridge, MA, October 9, 2013.
11. Garg R.J., Kantarjian H., O'Brien S., Quintas-Cardama A., Faderl S., Estrov Z., et al. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood 2009, 114:4361-4368.
12. Nicolini F.E., Ibrahim A.R., Soverini S., Martinelli G., Muller M.C., Hochhaus A., et al. The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis. Haematologica 2013, 98:1510-1516.
13. Ibrahim A.R., Paliompeis C., Bua M., Milojkovic D., Szydlo R., Khorashad J.S., et al. Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy. Blood 2010, 116:5497-5500.
14. Kantarjian H.M., Cortes J.E., Kim D.W., Khoury H.J., Brummendorf T.H., Porkka K., et al. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Blood 2014, 123:1309-1318.
15. National Comprehensive Cancer Network Clinical practice guidelines in oncology: chronic myelogenous leukemia V2.1014 2014, NCCN.
16. Cortes J.E., Kim D.-W., Pinilla-Ibarz J., le Coutre P., Paquette R., Chuah C., et al. A pivotal phase 2 trial of ponatinib in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) Resistant or intolerant to dasatinib or nilotinib, or with the T315I BCR-ABL mutation: 12-month follow-up of the PACE trial. ASH Annu Meeting Abstr 2012, 120:163.
17. Cortes J.E., Kim D.W., Pinilla-Ibarz J., le Coutre P., Paquette R., Chuah C., et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013, 369:1783-1796.
18. Cortes J.E., Kantarjian H., Shah N.P., Bixby D., Mauro M.J., Flinn I., et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012, 367:2075-2088.
19. Khoury H.J., Cortes J.E., Kantarjian H.M., Gambacorti-Passerini C., Baccarani M., Kim D.W., et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood 2012, 119:3403-3412.
20. Quintas-Cardama A., Kantarjian H., Jones D., Nicaise C., O'Brien S., Giles F., et al. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood 2007, 109:497-499.
21. Giles F.J., Abruzzese E., Rosti G., Kim D.W., Bhatia R., Bosly A., et al. Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia 2010, 24:1299-1301.
22. Nicolini F.E. Expanding nilotinib access in clinical trials (ENACT) study in adult patients (Pts.) with imatinib-resistant or -intolerant chronic myeloid leukaemia (CML): Subgroup analysis of patients who failed prior dasatinib therapy. Haematologica 2009, 94:257. abstr 0633.
23. Garcia-Gutierrez J.V., Maestro B., Casado L.F., Perez-Encinas M., Massague I., de Paz R., et al. Outcomes of chronic myeloid leukemia (CML) Patients who stopped second generation tyrosine kinase inhibitors (2GTKIs) as second line treatment. Results of the CML Spanish National Registry (RELMC). ASH Annual Meeting Abstr 2012, 120:3764.
24. Russo Rossi A., Breccia M., Luciano L., Gozzini A., Abruzzese E., Martino M., et al. Outcome of patients with chronic phase CML treated with dasatinib or nilotinib after failure of second prior TKIs. EHA Meeting Abstr 2011.
25. Cortes J., Quintas-Cardama A., Jabbour E., O'Brien S., Verstovsek S., Borthakur G., et al. The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint?. Clin Lymphoma Myeloma Leukemia 2011, 11:421-426.
26. Nicolini F.E., Mauro M.J., Martinelli G., Kim D.-W., Soverini S., Müller M.C., et al. Epidemiologic study on survival of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. Blood 2009, 114:5271-5278.
27. NCCN NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia, v.2.2014 2013, National Comprehensive Cancer Network.
28. Kantarjian H., O'Brien S., Shan J., Huang X., Garcia-Manero G., Faderl S., et al. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?. Cancer 2008, 112:837-845.
29. Schrover R.J., Adena M.A., De Abreu Lourenco R., Prince H.M., Seymour J.F., Wonder M.J. Development of a predictive population survival model according to the cytogenetic response rate for patients with chronic myeloid leukemia in the chronic phase. Leukemia Lymphoma 2006, 47:1069-1081.
30. Oriana C., Martin H., Toby P., Chris C., Ruth G., Claudius R., et al. Complete cytogenetic response and major molecular response as surrogate outcomes for overall survival in first-line treatment of chronic myelogenous leukemia: a case study for technology appraisal on the basis of surrogate outcomes evidence. Value Health: J Int Soc Pharmacoecon Outcomes Res 2013, 16:1081-1090.
31. Taylor R.S., Elston J. The use of surrogate outcomes in model-based cost-effectiveness analyses: a survey of UK Health Technology Assessment reports. Health Technol Assess 2009, 3. iii, ix-xi, 1-50.
32. Teva Pharmaceuticals USA Inc. SYNBRIO prescribing information 2012.
33. Akard L.P., Kantarjian H., Nicolini F.E., Wetzler M., Lipton J.H., Baccarani M., et al. Omacetaxine mepesuccinate in chronic-phase chronic myeloid leukemia (CML) in patients resistant, intolerant, or both to two or more tyrosine-kinase inhibitors (TKIs). ASCO Meeting Abstr 2012, 30:6596.